Emily Eul

Emily Eul

Auto-generated profile, based on publicly available information

Emily Eul

Department of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, Missouri

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2021 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
ACAude-Helene Capietto
Aude-Helene Capietto
SLSeunghyun Lee
Seunghyun Lee
DCDavid Clever
David Clever
EEEmily Eul
Emily Eul
HEHaley Ellis
Haley Ellis
RFRoberta Faccio
Roberta Faccio
Osteoclast (OC) blockade has been successful in reducing tumor growth in bone in preclinical settings, but antiresorptive drugs, such as zoledronic acid (ZA), fail to improve the overall survival rate of patients with bone metastasis despite ameliorating skeletal complications. To address this unmet clinical need, we interrogated what other cells modulated tumor growth in bone in addition to OCs. Because myeloid-derived suppressor cells (MDSC)—heterogeneous populations expressing CD11b, Ly6C, and Ly6G markers—originate in the bone marrow and promote tumor progression, we hypothesized that their accumulation hinders ZA antitumor effects. By using a murine model of bone metastasis insensitive to OC blockade, we assessed the antitumor effect of MDSC depletion using anti-Gr1 in mice bearing skeletal lung [Lewis lung carcinoma (LLC)], melanoma (B16-F10), and mammary (4T1) tumors. Differently from soft tissue tumors, anti-Gr1 did not reduce bone metastases and led to the paradoxical accumulation of bone marrow–resident CD11b+Ly6CintLy6Gint cells that differentiated into OCs when cultured in vitro. Anti-Gr1–mediated depletion of Ly6G+ granulocytic MDSCs combined with ZA-induced OC blockade reduced growth of established skeletal metastases compared with each agent alone. CD15+ granulocytic populations were increased in patients with breast cancer with progressive bone disease after antiresorptive treatment compared with those with stable bone disease. We provide evidence that antiresorptive therapies fail to reduce bone metastases in the presence of elevated granulocytic populations and that effective treatment of established skeletal metastases requires combinatorial depletion of granulocytes and OC blockade.

4 April 2023
Verified
Other
Open access
ACAude-Helene Capietto
Aude-Helene Capietto
SLSeunghyun Lee
Seunghyun Lee
DCDavid Clever
David Clever
EEEmily Eul
Emily Eul
HEHaley Ellis
Haley Ellis
RFRoberta Faccio
Roberta Faccio
Anti-Gr1 Ab treatment reduces soft tissue tumor growth

4 April 2023
Verified
Other
Open access
ACAude-Helene Capietto
Aude-Helene Capietto
SLSeunghyun Lee
Seunghyun Lee
DCDavid Clever
David Clever
EEEmily Eul
Emily Eul
HEHaley Ellis
Haley Ellis
RFRoberta Faccio
Roberta Faccio
Osteoclast (OC) blockade has been successful in reducing tumor growth in bone in preclinical settings, but antiresorptive drugs, such as zoledronic acid (ZA), fail to improve the overall survival rate of patients with bone metastasis despite ameliorating skeletal complications. To address this unmet clinical need, we interrogated what other cells modulated tumor growth in bone in addition to OCs. Because myeloid-derived suppressor cells (MDSC)—heterogeneous populations expressing CD11b, Ly6C, and Ly6G markers—originate in the bone marrow and promote tumor progression, we hypothesized that their accumulation hinders ZA antitumor effects. By using a murine model of bone metastasis insensitive to OC blockade, we assessed the antitumor effect of MDSC depletion using anti-Gr1 in mice bearing skeletal lung [Lewis lung carcinoma (LLC)], melanoma (B16-F10), and mammary (4T1) tumors. Differently from soft tissue tumors, anti-Gr1 did not reduce bone metastases and led to the paradoxical accumulation of bone marrow–resident CD11b+Ly6CintLy6Gint cells that differentiated into OCs when cultured in vitro. Anti-Gr1–mediated depletion of Ly6G+ granulocytic MDSCs combined with ZA-induced OC blockade reduced growth of established skeletal metastases compared with each agent alone. CD15+ granulocytic populations were increased in patients with breast cancer with progressive bone disease after antiresorptive treatment compared with those with stable bone disease. We provide evidence that antiresorptive therapies fail to reduce bone metastases in the presence of elevated granulocytic populations and that effective treatment of established skeletal metastases requires combinatorial depletion of granulocytes and OC blockade.


4 April 2023
Verified
Other
Open access
ACAude-Helene Capietto
Aude-Helene Capietto
SLSeunghyun Lee
Seunghyun Lee
DCDavid Clever
David Clever
EEEmily Eul
Emily Eul
HEHaley Ellis
Haley Ellis
RFRoberta Faccio
Roberta Faccio
Bone marrow CD11b+/Ly6Cint/Ly6Gint cells lack immune suppressive capacities

4 April 2023
Verified
Other
Open access
ACAude-Helene Capietto
Aude-Helene Capietto
SLSeunghyun Lee
Seunghyun Lee
DCDavid Clever
David Clever
EEEmily Eul
Emily Eul
HEHaley Ellis
Haley Ellis
RFRoberta Faccio
Roberta Faccio
In vivo anti-Gr1 Ab treatment fails to deplete CD11b+/Gr1+ myeloid cells in bone marrow of mice with skeletal tumors